Skip to main content
SpringerLink
Log in
Book cover

Inflammatory Disorders of the Nervous System pp 203–225Cite as

Immunopathogenesis and Treatment of Guillain-Barre Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy

  • Chapter
  • First Online:

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

This chapter discusses the clinical manifestations, pathogenesis, and treatment of Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP), including recent advances in immunopathogenesis as well as the treatments in pipeline. GBS and CIDP are part of the spectrum of autoimmune-mediated neuropathy. The target antigen remains elusive in CIDP and acute inflammatory demyelinating polyneuropathy, the most common variant of GBS in North America. Autoimmunity against different gangliosides is involved in the pathogenesis of GBS variants, i.e., acute motor axonal neuropathy, Miller Fisher syndrome, and acute motor and sensory axonal neuropathy, as well as their sub-variants. As GBS is a monophasic disease, immunomodulatory treatment, currently consisting of intravenous immunoglobulin infusions or plasma exchange, is required only during the acute phase, unless there are relapses. On the other hand, maintenance treatment with the aforementioned treatment modalities, as well as corticosteroids or other immunosuppressants, is frequently needed in CIDP patients. Further advances in the understanding of immunopathogenesis of these diseases will likely result in development of new treatments involving targeted immunotherapy.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Yuki N, Hartung HP. Guillain-Barre syndrome. N Engl J Med. 2012;366:2294–304.

    Article  CAS  PubMed  Google Scholar 

  2. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469–82.

    Article  PubMed  CAS  Google Scholar 

  3. van den Berg B, Fokke C, Drenthen J, van Doorn PA, Jacobs BC. Paraparetic Guillain-Barre syndrome. Neurology. 2014;82:1984–9.

    Article  PubMed  Google Scholar 

  4. Kuwabara S, Yuki N. Axonal Guillain-Barre syndrome: concepts and controversies. Lancet Neurol. 2013;12:1180–8.

    Article  PubMed  Google Scholar 

  5. Hiraga A, Kuwabara S, Ogawara K, et al. Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain-Barre syndrome. Neurology. 2005;64:856–60.

    Article  CAS  PubMed  Google Scholar 

  6. Aranyi Z, Kovacs T, Sipos I, Bereczki D. Miller Fisher syndrome: brief overview and update with a focus on electrophysiological findings. Eur J Neurol. 2012;19:15–20. e11–13

    Article  CAS  PubMed  Google Scholar 

  7. Wakerley BR, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2014;85:339–44.

    Article  PubMed  Google Scholar 

  8. Wakerley BR, Yuki N. Guillain-Barre syndrome. Expert Rev Neurother. 2015;15:847–9.

    Article  CAS  PubMed  Google Scholar 

  9. Uncini A, Manzoli C, Notturno F, Capasso M. Pitfalls in electrodiagnosis of Guillain-Barre syndrome subtypes. J Neurol Neurosurg Psychiatry. 2010;81:1157–63.

    Article  PubMed  Google Scholar 

  10. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine. 1969;48:173–215.

    Article  CAS  PubMed  Google Scholar 

  11. Prineas JW. Pathology of the Guillain-Barre syndrome. Ann Neurol. 1981;9(Suppl):6–19.

    Article  PubMed  Google Scholar 

  12. Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39:625–35.

    Article  CAS  PubMed  Google Scholar 

  13. Griffin JW, Li CY, Ho TW, et al. Guillain-Barre syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain (A Journal of Neurology). 1995;118(Pt 3):577–95.

    Article  Google Scholar 

  14. Phillips MS, Stewart S, Anderson JR. Neuropathological findings in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry. 1984;47:492–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Jacobs BC, Rothbarth PH, van der Meche FG, et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology. 1998;51:1110–5.

    Article  CAS  PubMed  Google Scholar 

  16. Yuki N, Taki T, Inagaki F, et al. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med. 1993;178:1771–5.

    Article  CAS  PubMed  Google Scholar 

  17. Koga M, Takahashi M, Masuda M, Hirata K, Yuki N. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barre syndrome. Neurology. 2005;65:1376–81.

    Article  CAS  PubMed  Google Scholar 

  18. Tam CC, Rodrigues LC, Petersen I, Islam A, Hayward A, O'Brien SJ. Incidence of Guillain-Barre syndrome among patients with Campylobacter infection: a general practice research database study. J Infect Dis. 2006;194:95–7.

    Article  PubMed  Google Scholar 

  19. Kuwabara S, Ogawara K, Misawa S, et al. Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barre syndrome? Neurology. 2004;63:529–33.

    Article  CAS  PubMed  Google Scholar 

  20. Illa I, Ortiz N, Gallard E, Juarez C, Grau JM, Dalakas MC. Acute axonal Guillain-Barre syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol. 1995;38:218–24.

    Article  CAS  PubMed  Google Scholar 

  21. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain (A Journal of Neurology). 2002;125:2591–625.

    Article  Google Scholar 

  22. Kusunoki S, Kaida K. Antibodies against ganglioside complexes in Guillain-Barre syndrome and related disorders. J Neurochem. 2011;116:828–32.

    Article  CAS  PubMed  Google Scholar 

  23. Dalakas MC. Pathogenesis of immune-mediated neuropathies. Biochim Biophys Acta. 1852;2015:658–66.

    Google Scholar 

  24. Gong Y, Tagawa Y, Lunn MP, et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain (A Journal of Neurology). 2002;125:2491–506.

    Article  CAS  Google Scholar 

  25. McGonigal R, Rowan EG, Greenshields KN, et al. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain (A Journal of Neurology). 2010;133:1944–60.

    Article  Google Scholar 

  26. Burkel WE. The histological fine structure of perineurium. Anat Rec. 1967;158:177–89.

    Article  CAS  PubMed  Google Scholar 

  27. Olsson Y. Microenvironment of the peripheral nervous system under normal and pathological conditions. Crit Rev Neurobiol. 1990;5:265–311.

    CAS  PubMed  Google Scholar 

  28. Sawai S, Satoh M, Mori M, et al. Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barre syndrome. Neurology. 2014;83:113–7.

    Article  CAS  PubMed  Google Scholar 

  29. Gatto CL, Walker BJ, Lambert S. Local ERM activation and dynamic growth cones at Schwann cell tips implicated in efficient formation of nodes of Ranvier. J Cell Biol. 2003;162:489–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Li S, Yu M, Li H, Zhang H, Jiang Y. IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barre syndrome. Mediators Inflamm. 2012;2012:260473.

    PubMed  PubMed Central  Google Scholar 

  31. Li S, Jin T, Zhang HL, et al. Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barre syndrome and downregulated by IVIg treatments. Mediators Inflamm. 2014;2014:740947.

    PubMed  PubMed Central  Google Scholar 

  32. Maddur MS, Rabin M, Hegde P, et al. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barre syndrome patients. Immunol Res. 2014;60:320–9.

    Article  CAS  PubMed  Google Scholar 

  33. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775–87.

    Article  CAS  PubMed  Google Scholar 

  34. Waksman BH, Adams RD. Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J Exp Med. 1955;102:213–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Rostami A, Gregorian SK, Brown MJ, Pleasure DE. Induction of severe experimental autoimmune neuritis with a synthetic peptide corresponding to the 53-78 amino acid sequence of the myelin P2 protein. J Neuroimmunol. 1990;30:145–51.

    Article  CAS  PubMed  Google Scholar 

  36. Soliven B. Animal models of autoimmune neuropathy. ILAR (Journal/National Research Council, Institute of Laboratory Animal Resources). 2014;54:282–90.

    Article  CAS  Google Scholar 

  37. Astrom KE, Webster HD, Arnason BG. The initial lesion in experimental allergic neuritis. A phase and electron microscopic study. J Exp Med. 1968;128:469–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Taylor JM, Pollard JD. Dominance of autoreactive T cell-mediated delayed-type hypersensitivity or antibody-mediated demyelination results in distinct forms of experimental autoimmune neuritis in the Lewis rat. J Neuropathol Exp Neurol. 2001;60:637–46.

    Article  CAS  PubMed  Google Scholar 

  39. Lonigro A, Devaux JJ. Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis. Brain (A Journal of neurology). 2009;132:260–73.

    Article  Google Scholar 

  40. Devaux JJ. Antibodies to gliomedin cause peripheral demyelinating neuropathy and the dismantling of the nodes of Ranvier. Am J Pathol. 2012;181:1402–13.

    Article  CAS  PubMed  Google Scholar 

  41. Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol. 2001;49:712–20.

    Article  CAS  PubMed  Google Scholar 

  42. Susuki K, Yuki N, Schafer DP, et al. Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol. 2012;233:534–42.

    Article  CAS  PubMed  Google Scholar 

  43. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol. 2008;7:939–50.

    Article  PubMed  Google Scholar 

  44. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barre syndrome. Arch Neurol. 2001;58:893–8.

    Article  CAS  PubMed  Google Scholar 

  45. Sharshar T, Chevret S, Bourdain F, Raphael JC. French Cooperative Group on Plasma Exchange in Guillain-Barre S. Early predictors of mechanical ventilation in Guillain-Barre syndrome. Crit Care Med. 2003;31:278–83.

    Article  PubMed  Google Scholar 

  46. Ropper AH, Kehne SM. Guillain-Barre syndrome: management of respiratory failure. Neurology. 1985;35:1662–5.

    Article  CAS  PubMed  Google Scholar 

  47. Dimario Jr FJ, Edwards C. Autonomic dysfunction in childhood Guillain-Barre syndrome. J Child Neurol. 2012;27:581–6.

    Article  PubMed  Google Scholar 

  48. Ruts L, Drenthen J, Jongen JL, et al. Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology. 2010;75:1439–47.

    Article  CAS  PubMed  Google Scholar 

  49. Hiraga A, Nagumo K, Suzuki K, Sakakibara Y, Kojima S. [A patient with Guillain-Barre syndrome and recurrent episodes of ST elevation and left ventricular hypokinesis in the anterior wall]. No to shinkei =. Brain Nerve. 2003;55:517–20.

    PubMed  Google Scholar 

  50. Burns TM, Lawn ND, Low PA, Camilleri M, Wijdicks EF. Adynamic ileus in severe Guillain-Barre syndrome. Muscle Nerve. 2001;24:963–5.

    Article  CAS  PubMed  Google Scholar 

  51. Sakakibara R, Hattori T, Kuwabara S, Yamanishi T, Yasuda K. Micturitional disturbance in patients with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 1997;63:649–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Sakakibara R, Uchiyama T, Kuwabara S, et al. Prevalence and mechanism of bladder dysfunction in Guillain-Barre Syndrome. NeurourolUrodyn. 2009;28:432–7.

    Google Scholar 

  53. Amatya B, Khan F, Whishaw M, Pallant JF. Guillain-Barre syndrome: prevalence and long-term factors impacting bladder function in an Australian community cohort. J Clin Neurol. 2013;9:144–50.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Winer JB, Hughes RA, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry. 1988;51:605–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Hughes RA, van Doorn PA. Corticosteroids for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2012;8:CD001446.

    Google Scholar 

  56. Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barre syndrome. Ann Neurol. 1987;22:753–61.

    Google Scholar 

  57. Appropriate number of plasma exchanges in Guillain-Barre syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Ann Neurol. 1997;41:298–306.

    Google Scholar 

  58. Plasmapheresis and acute Guillain-Barre syndrome. The Guillain-Barre syndrome Study Group. Neurology. 1985;35:1096–1104.

    Google Scholar 

  59. Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain (A Journal of Neurology). 2007;130:2245–57.

    Article  Google Scholar 

  60. Greenwood RJ, Newsom-Davis J, Hughes RA, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984;1:877–9.

    Article  CAS  PubMed  Google Scholar 

  61. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med. 1992;326:1123–9.

    Article  PubMed  Google Scholar 

  62. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Lancet. 1997;349:225–30.

    Google Scholar 

  63. Korinthenberg R, Schessl J, Kirschner J, Monting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial. Pediatrics. 2005;116:8–14.

    Article  PubMed  Google Scholar 

  64. Kleyweg RP, van der Meche FG. Treatment related fluctuations in Guillain-Barre syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry. 1991;54:957–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol. 2009;66:597–603.

    Article  CAS  PubMed  Google Scholar 

  66. Dada MA, Kaplan AA. Plasmapheresis treatment in Guillain-Barre syndrome: potential benefit over IVIg in patients with axonal involvement. Ther Apher Dial (Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy). 2004;8:409–12.

    Article  CAS  Google Scholar 

  67. Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology. 2007;68:1144–6.

    Article  CAS  PubMed  Google Scholar 

  68. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552–9.

    Article  CAS  PubMed  Google Scholar 

  69. Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain (A Journal of Neurology). 2008;131:1197–208.

    Article  Google Scholar 

  70. Phongsisay V, Susuki K, Matsuno K, et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome. J Neuroimmunol. 2008;205:101–4.

    Article  CAS  PubMed  Google Scholar 

  71. Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. Eur J Neurol. 2010;17:356–63.

    Article  CAS  PubMed  Google Scholar 

  72. Gorson KC, Katz J. Chronic inflammatory demyelinating polyneuropathy. Neurol Clin. 2013;31:511–32.

    Article  PubMed  Google Scholar 

  73. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve. 2001;24:311–24.

    Article  CAS  PubMed  Google Scholar 

  74. Boukhris S, Magy L, Khalil M, Sindou P, Vallat JM. Pain as the presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). J Neurol Sci. 2007;254:33–8.

    Article  CAS  PubMed  Google Scholar 

  75. Henderson RD, Sandroni P, Wijdicks EF. Chronic inflammatory demyelinating polyneuropathy and respiratory failure. J Neurol. 2005;252:1235–7.

    Article  PubMed  Google Scholar 

  76. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc. 1975;50:621–37.

    CAS  PubMed  Google Scholar 

  77. Mathey EK, Park SB, Hughes RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry. 2015;86:973–85.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Viala K, Maisonobe T, Stojkovic T, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15:50–6.

    Article  CAS  PubMed  Google Scholar 

  79. Oh SJ, Joy JL, Kuruoglu R. "Chronic sensory demyelinating neuropathy": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry. 1992;55:677–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Rajabally YA, Wong SL. Chronic inflammatory pure sensory polyradiculoneuropathy: a rare CIDP variant with unusual electrophysiology. J Clin Neuromuscul Dis. 2012;13:149–52.

    Article  PubMed  Google Scholar 

  81. van Dijk GW, Notermans NC, Franssen H, Wokke JH. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long-term follow-up study. J Neurol. 1999;246:1134–9.

    Article  PubMed  Google Scholar 

  82. Simmons Z, Tivakaran S. Acquired demyelinating polyneuropathy presenting as a pure clinical sensory syndrome. Muscle Nerve. 1996;19:1174–6.

    Article  CAS  PubMed  Google Scholar 

  83. Yato M, Ohkoshi N, Sato A, Shoji S, Kusunoki S. Ataxic form of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Eur J Neurol. 2000;7:227–30.

    Article  CAS  PubMed  Google Scholar 

  84. Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJ. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology. 2004;63:1662–9.

    Article  CAS  PubMed  Google Scholar 

  85. Yiannikas C, Vucic S. Utility of somatosensory evoked potentials in chronic acquired demyelinating neuropathy. Muscle Nerve. 2008;38:1447–54.

    Article  PubMed  Google Scholar 

  86. Sabatelli M, Madia F, Mignogna T, Lippi G, Quaranta L, Tonali P. Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol. 2001;248:772–7.

    Article  CAS  PubMed  Google Scholar 

  87. Hattori N, Misu K, Koike H, et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001;184:57–63.

    Article  CAS  PubMed  Google Scholar 

  88. Pitarokoili K, Schlamann M, Kerasnoudis A, Gold R, Yoon MS. Comparison of clinical, electrophysiological, sonographic and MRI features in CIDP. J Neurol Sci. 2015;357:198–203.

    Article  CAS  PubMed  Google Scholar 

  89. Matsuda M, Ikeda S, Sakurai S, Nezu A, Yanagisawa N, Inuzuka T. Hypertrophic neuritis due to chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a postmortem pathological study. Muscle Nerve. 1996;19:163–9.

    Article  CAS  PubMed  Google Scholar 

  90. Vital C, Vital A, Lagueny A, et al. Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases. Ultrastruct Pathol. 2000;24:363–9.

    Article  CAS  PubMed  Google Scholar 

  91. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989;46:878–84.

    Article  CAS  PubMed  Google Scholar 

  92. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997;48:321–8.

    Article  CAS  PubMed  Google Scholar 

  93. Harvey GK, Pollard JD, Schindhelm K, Antony J. Chronic experimental allergic neuritis. An electrophysiological and histological study in the rabbit. J Neurol Sci. 1987;81:215–25.

    Article  CAS  PubMed  Google Scholar 

  94. Adam AM, Atkinson PF, Hall SM, Hughes RA, Taylor WA. Chronic experimental allergic neuritis in Lewis rats. Neuropathol Appl Neurobiol. 1989;15:249–64.

    Article  CAS  PubMed  Google Scholar 

  95. Crino PB, Grossman RI, Rostami A. Magnetic resonance imaging of the cauda equina in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 1993;33:311–3.

    Article  CAS  PubMed  Google Scholar 

  96. Morgan GW, Barohn RJ, Bazan 3rd C, King RB, Klucznik RP. Nerve root enhancement with MRI in inflammatory demyelinating polyradiculoneuropathy. Neurology. 1993;43:618–20.

    Article  CAS  PubMed  Google Scholar 

  97. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain (A Journal of Neurology). 1987;110(Pt 6):1617–30.

    Article  Google Scholar 

  98. Chio A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry. 2007;78:1349–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Gibbels E, Diederich N. Human immunodeficiency virus (HIV)-related chronic relapsing inflammatory demyelinating polyneuropathy with multifocal unusual onion bulbs in sural nerve biopsy. A clinicomorphological study with qualitative and quantitative light and electron microscopy. Acta Neuropathol. 1988;75:529–34.

    Article  CAS  PubMed  Google Scholar 

  100. Chimowitz MI, Audet AM, Hallet A, Kelly Jr JJ. HIV-associated CIDP. Muscle Nerve. 1989;12:695–6.

    Article  CAS  PubMed  Google Scholar 

  101. Bird SJ, Brown MJ, Shy ME, Scherer SS. Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Neurology. 1996;46:822–4.

    Article  CAS  PubMed  Google Scholar 

  102. Weiss MD, Luciano CA, Semino-Mora C, Dalakas MC, Quarles RH. Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology. 1998;51:1738–41.

    Article  CAS  PubMed  Google Scholar 

  103. Rousseau A, Salachas F, Baccard M, Delattre JY, Sanson M. Chronic inflammatory polyneuropathy revealing malignant melanoma. J Neurooncol. 2005;71:335–6.

    Article  CAS  PubMed  Google Scholar 

  104. Noronha AB, Harper JR, Ilyas AA, Reisfeld RA, Quarles RH. Myelin-associated glycoprotein shares an antigenic determinant with a glycoprotein of human melanoma cells. J Neurochem. 1986;47:1558–65.

    Article  CAS  PubMed  Google Scholar 

  105. Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve. 1996;19:474–87.

    Article  CAS  PubMed  Google Scholar 

  106. Chi LJ, Xu WH, Zhang ZW, Huang HT, Zhang LM, Zhou J. Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15:345–56.

    Article  CAS  PubMed  Google Scholar 

  107. Winer J, Hughes S, Cooper J, Ben-Smith A, Savage C. gamma delta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy. J Neurol. 2002;249:616–21.

    Article  PubMed  Google Scholar 

  108. Renaud S, Erne B, Fuhr P, et al. Matrix metalloproteinases-9 and -2 in secondary vasculitic neuropathies. Acta Neuropathol. 2003;105:37–42.

    Article  CAS  PubMed  Google Scholar 

  109. Schneider-Hohendorf T, Schwab N, Uceyler N, Gobel K, Sommer C, Wiendl H. CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2012;78:402–8.

    Article  CAS  PubMed  Google Scholar 

  110. Mausberg AK, Dorok M, Stettner M, et al. Recovery of the T-cell repertoire in CIDP by IV immunoglobulins. Neurology. 2013;80:296–303.

    Article  CAS  PubMed  Google Scholar 

  111. Chi LJ, Wang HB, Wang WZ. Impairment of circulating CD4+CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2008;13:54–63.

    Article  CAS  PubMed  Google Scholar 

  112. Sanvito L, Makowska A, Gregson N, Nemni R, Hughes RA. Circulating subsets and CD4(+)CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy. Autoimmunity. 2009;42:667–77.

    Article  CAS  PubMed  Google Scholar 

  113. Ledbetter JA, Imboden JB, Schieven GL, et al. CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood. 1990;75:1531–9.

    CAS  PubMed  Google Scholar 

  114. Khalili-Shirazi A, Gregson NA, Londei M, Summers L, Hughes RA. The distribution of CD1 molecules in inflammatory neuropathy. J Neurol Sci. 1998;158:154–63.

    Article  CAS  PubMed  Google Scholar 

  115. Van Rhijn I, Van den Berg LH, Bosboom WM, Otten HG, Logtenberg T. Expression of accessory molecules for T-cell activation in peripheral nerve of patients with CIDP and vasculitic neuropathy. Brain (A Journal of Neurology). 2000;123(Pt 10):2020–9.

    Article  Google Scholar 

  116. Sommer C, Koch S, Lammens M, Gabreels-Festen A, Stoll G, Toyka KV. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology. 2005;65:1924–9.

    Article  CAS  PubMed  Google Scholar 

  117. Dalakas MC, Engel WK. Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch Neurol. 1980;37:637–40.

    Article  CAS  PubMed  Google Scholar 

  118. Hays AP, Lee SS, Latov N. Immune reactive C3d on the surface of myelin sheaths in neuropathy. J Neuroimmunol. 1988;18:231–44.

    Article  CAS  PubMed  Google Scholar 

  119. Yan WX, Taylor J, Andrias-Kauba S, Pollard JD. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol. 2000;47:765–75.

    Article  CAS  PubMed  Google Scholar 

  120. Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352:1343–56.

    Article  PubMed  Google Scholar 

  121. Dalakas MC, Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011;7:507–17.

    Article  PubMed  Google Scholar 

  122. Yan WX, Archelos JJ, Hartung HP, Pollard JD. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:286–92.

    Article  CAS  PubMed  Google Scholar 

  123. Devaux JJ, Odaka M, Yuki N. Nodal proteins are target antigens in Guillain-Barre syndrome. J Peripher Nerv Syst. 2012;17:62–71.

    Article  CAS  PubMed  Google Scholar 

  124. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 2013;73:370–80.

    Article  CAS  PubMed  Google Scholar 

  125. Labasque M, Hivert B, Nogales-Gadea G, Querol L, Illa I, Faivre-Sarrailh C. Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. J Biol Chem. 2014;289:7907–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Miura Y, Devaux JJ, Fukami Y, et al. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain (A Journal of Neurology). 2015;138:1484–91.

    Article  Google Scholar 

  127. Devaux JJ, Miura Y, Fukami Y, et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology. 2016;86:800–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. McCombe PA, van der Kreek SA, Pender MP. The effects of prophylactic cyclosporin A on experimental allergic neuritis (EAN) in the Lewis rat. Induction of relapsing EAN using low dose cyclosporin A. J Neuroimmunol. 1990;28:131–40.

    Article  CAS  PubMed  Google Scholar 

  129. Salomon B, Rhee L, Bour-Jordan H, et al. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med. 2001;194:677–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Kim HJ, Jung CG, Jensen MA, Dukala D, Soliven B. Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy. J Immunol. 2008;181:8753–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Hughes RA, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2012;8:CD002062.

    Google Scholar 

  132. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;12:CD001797.

    Google Scholar 

  133. Mehndiratta MM, Hughes RA. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2012;9:CD003906.

    Google Scholar 

  134. Cocito D, Paolasso I, Antonini G, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2010;17:289–94.

    Article  CAS  PubMed  Google Scholar 

  135. Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11:136–41.

    Article  CAS  PubMed  Google Scholar 

  136. van Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9:245–53.

    Article  PubMed  CAS  Google Scholar 

  137. Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol. 2005;62:249–54.

    Article  PubMed  Google Scholar 

  138. Iijima M, Yamamoto M, Hirayama M, et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology. 2005;64:1471–5.

    Article  CAS  PubMed  Google Scholar 

  139. Buttmann M, Kaveri S, Hartung HP. Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends Pharmacol Sci. 2013;34:445–57.

    Article  CAS  PubMed  Google Scholar 

  140. Wong AH, Fukami Y, Sudo M, Kokubun N, Hamada S, Yuki N. Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2016;87:275–9.

    Article  PubMed  Google Scholar 

  141. Brannagan 3rd TH. Intravenous gamma globulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology. 2002;59:S33–40.

    Article  CAS  PubMed  Google Scholar 

  142. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136–44.

    Article  CAS  PubMed  Google Scholar 

  143. Markvardsen LH, Debost JC, Harbo T, et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2013;20:836–42.

    Article  CAS  PubMed  Google Scholar 

  144. Markvardsen LH, Harbo T, Sindrup SH, et al. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2014;21:1465–70.

    Article  CAS  PubMed  Google Scholar 

  145. Kuitwaard K, van den Berg LH, Vermeulen M, et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2010;81:1374–9.

    Article  CAS  PubMed  Google Scholar 

  146. Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11:493–502.

    Article  CAS  PubMed  Google Scholar 

  147. Dyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314:461–5.

    Article  CAS  PubMed  Google Scholar 

  148. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain (A Journal of Neurology). 1996;119(Pt 4):1055–66.

    Article  Google Scholar 

  149. Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2004:CD003280.

    Google Scholar 

  150. Dyck PJ, O'Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology. 1985;35:1173–6.

    Article  CAS  PubMed  Google Scholar 

  151. Stewart JD, McKelvey R, Durcan L, Carpenter S, Karpati G. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics. J Neurol Sci. 1996;142:59–64.

    Article  CAS  PubMed  Google Scholar 

  152. Haq RU, Pendlebury WW, Fries TJ, Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy in diabetic patients. Muscle Nerve. 2003;27:465–70.

    Article  PubMed  Google Scholar 

  153. Group RMCT. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 2009;8:158–64.

    Article  CAS  Google Scholar 

  154. Hadden RD, Sharrack B, Bensa S, Soudain SE, Hughes RA. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1999;53:57–61.

    Article  CAS  PubMed  Google Scholar 

  155. Brannagan 3rd TH, Pradhan A, Heiman-Patterson T, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology. 2002;58:1856–8.

    Article  CAS  PubMed  Google Scholar 

  156. Visudtibhan A, Chiemchanya S, Visudhiphan P. Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy. Pediatr Neurol. 2005;33:368–72.

    Article  PubMed  Google Scholar 

  157. Bedi G, Brown A, Tong T, Sharma KR. Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry. 2010;81:634–6.

    Article  PubMed  Google Scholar 

  158. Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology. 2004;63:715–7.

    Article  CAS  PubMed  Google Scholar 

  159. Press R, Askmark H, Svenningsson A, et al. Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP. J Neurol Neurosurg Psychiatry. 2014;85:618–24.

    Article  CAS  PubMed  Google Scholar 

  160. Benedetti L, Briani C, Franciotta D, et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry. 2011;82:306–8.

    Article  CAS  PubMed  Google Scholar 

  161. Querol L, Rojas-Garcia R, Diaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015;2:e149.

    Article  PubMed  PubMed Central  Google Scholar 

  162. Marsh EA, Hirst CL, Llewelyn JG, et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol. 2010;257:913–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Chicago Medical Center, Department of Neurology, Chicago, IL, USA

    Elena Grebenciucova & Kourosh Rezania MD

Authors
  1. Elena Grebenciucova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kourosh Rezania MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kourosh Rezania MD .

Editor information

Editors and Affiliations

  1. Department of Neurology, LSU Health Sciences Center, Shreveport, Louisiana, USA

    Alireza Minagar

  2. Department of Molecular and Cellular Physiology, LSU Health Sciences Center, Shreveport, Louisiana, USA

    J. Steven Alexander

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Grebenciucova, E., Rezania, K. (2017). Immunopathogenesis and Treatment of Guillain-Barre Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy. In: Minagar, A., Alexander, J. (eds) Inflammatory Disorders of the Nervous System. Current Clinical Neurology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-51220-4_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-51220-4_10

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-51218-1

  • Online ISBN: 978-3-319-51220-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation